The Diagnostic Multiplier™: A Framework for Adjusting Disease Prevalence Based on Real World Diagnostic Capture

By Cynthia Adinig

Key Findings and Summary

Disease prevalence is commonly treated as a direct reflection of biological occurrence. In practice, however, prevalence is also shaped by whether a condition is consistently recognized, evaluated, and diagnosed within real-world healthcare systems. A substantial body of research demonstrates that diagnostic variability, delayed recognition, and structural inequities can significantly distort observed disease burden across populations (National Academies of Sciences, Engineering, and Medicine 2017; Bailey et al. 2021).

The Diagnostic Multiplier™ (DM™) is a CYNAERA-developed framework designed to address this gap. Rather than assuming uniform detection, DMM™ incorporates diagnostic system performance into prevalence estimation. This allows for structured adjustment of observed prevalence to better approximate total disease burden. The framework is condition-agnostic and scalable across sectors, including oncology, chronic illness, women’s health, and global health modeling.

1. Problem Statement

Modern epidemiology relies on a foundational assumption: that recorded diagnoses provide a reasonable approximation of true disease prevalence. This assumption underlies how conditions are studied, funded, and prioritized across healthcare systems. However, it reflects a critical blind spot. Prevalence data does not measure disease directly. It measures what healthcare systems are able to detect. Diagnosis is not a neutral process. It is shaped by a sequence of clinical decisions, structural constraints, and contextual factors that determine whether a condition is recognized, investigated, and formally recorded. At each stage, cases may be delayed, misattributed, or lost entirely. As a result, observed prevalence reflects a filtered subset of total disease burden rather than a complete representation of it.

Diagnostic capture is influenced by multiple interacting forces. Clinical factors such as provider education, familiarity, and diagnostic thresholds affect recognition. Structural factors such as access to care, availability of testing, and referral pathways determine whether evaluation is completed. System-level patterns, including bias and variation in clinical suspicion, further shape who is diagnosed and when (Institute of Medicine 2003; Ward et al. 2004).

In oncology, these dynamics are visible in differences in stage at diagnosis and survival outcomes across populations, even when underlying incidence differs. Delayed recognition, uneven access to specialty care, and variation in provider suspicion contribute to later-stage presentation and worse outcomes, demonstrating that detection is a function of system performance as well as disease biology (Siegel et al. 2023; Clegg et al. 2002).

In parallel, environmental exposures introduce an additional layer of distortion that is not consistently captured in prevalence modeling. Factors such as air pollution, particulate matter, wildfire smoke, mold exposure, heat, humidity, and housing conditions can influence disease onset, severity, and progression. These exposures may alter symptom presentation, accelerate disease activity, or shift clinical thresholds for diagnosis. When environmental context is not fully integrated into diagnostic reasoning, conditions may be misclassified, attributed to unrelated causes, or identified only after progression.

These effects are particularly pronounced in conditions that rely on subjective criteria, specialist evaluation, or evolving clinical understanding. Fragmented care pathways, limited provider familiarity, and variability in environmental context increase the likelihood that cases remain unrecognized or inconsistently diagnosed (Jason et al. 1999; Hsu et al. 2015). The result is a persistent gap between visible burden and total burden. Visible burden reflects the portion of disease that successfully moves through diagnostic systems. Total burden reflects the full scope of disease across populations and environmental conditions. This gap is not a minor limitation. It has direct consequences for research prioritization, clinical trial design, resource allocation, and risk modeling. When prevalence is treated as complete, rather than conditional, existing distortions are reinforced and scaled.

The Diagnostic Multiplier™ is developed to address this limitation. It provides a structured method to account for how diagnostic systems perform in real-world conditions, including the influence of environmental exposures on disease expression and recognition. By incorporating these factors into prevalence estimation, the model enables a more accurate and system-aware representation of disease burden.

2. Conceptual Framework

The Diagnostic Multiplier™ reframes disease prevalence as a function of two interacting forces: biological occurrence and diagnostic system performance within real-world environments.

Traditional epidemiological models often assume that once a condition exists, it will be proportionally detected. In practice, diagnosis is neither automatic nor evenly distributed. It is the result of a multi-step process that includes symptom recognition, clinical interpretation, access to appropriate evaluation, and eventual confirmation. At each stage, cases may be delayed, misattributed, or never formally identified.

Within this framework, diagnosis is treated as a system-dependent process shaped by clinical, structural, and environmental context. Conditions do not simply appear in datasets because they exist. They appear because systems are capable of recognizing them under the conditions in which patients live and present. Diagnostic system performance is influenced by multiple layers of friction. These include social dynamics such as stigma, clinical factors such as provider education and familiarity, and structural constraints such as access to diagnostics and referral pathways. Critically, this performance is also shaped by environmental exposures that influence both disease expression and diagnostic interpretation.

Environmental factors including air quality, particulate matter, wildfire smoke, humidity, mold exposure, heat, housing conditions, and chemical exposures can alter symptom severity, trigger flares, accelerate disease progression, and change how conditions present clinically. In many cases, these environmental drivers are not fully integrated into diagnostic reasoning, leading to delayed recognition or misclassification of disease. As a result, observed prevalence reflects a filtered version of reality. It captures the subset of cases that successfully move through diagnostic systems operating within specific environmental and clinical contexts, rather than the total number of cases that exist across varying exposure conditions.

The Diagnostic Multiplier™ is designed to estimate this gap. By modeling diagnostic system performance alongside environmental and clinical influences on disease expression, it provides a structured method to approximate the portion of disease burden that remains unrecognized within existing systems. This approach enables prevalence to be interpreted not as a fixed biological measure, but as a dynamic output shaped by the interaction between disease, environment, and system capacity to detect it.

3. The Diagnostic Multiplier™ Model

At its core, the Diagnostic Multiplier™ translates qualitative insights about diagnostic systems into a quantitative adjustment of observed prevalence. The multiplier represents the degree to which diagnostic systems incompletely capture true disease burden. A value of 1.0 would imply perfect detection, where all existing cases are identified and recorded. In practice, no condition achieves this level of capture. Even in highly monitored diseases, variation in access, timing, and recognition introduces measurable gaps.

Core Equation

Adjusted Prevalence = Observed Prevalence × Diagnostic Multiplier

Rather than applying a fixed or arbitrary correction, the Diagnostic Multiplier™ is derived from a structured evaluation of condition-specific diagnostic dynamics. This evaluation considers how a condition moves through real-world clinical pathways, including where and why cases are most likely to be missed, delayed, or misclassified.

Importantly, the multiplier is not intended to override biological differences between conditions or populations. Instead, it adjusts for system performance, allowing observed prevalence to be interpreted in context. This distinction is critical. Two conditions with similar biological incidence may have very different observed prevalence depending on how effectively they are recognized. The Diagnostic Multiplier™ accounts for this variation by treating diagnostic capture as a measurable and adjustable component of prevalence.

4. Diagnostic Friction Domains

The Diagnostic Multiplier™ is informed by six core domains that represent common pathways through which cases are lost or delayed within diagnostic systems. These domains capture recurring patterns observed across conditions and healthcare settings.

Stigma Burden

Stigma influences whether symptoms are taken seriously by patients, providers, and institutions. Conditions associated with contested symptoms, gender bias, or historical dismissal are more likely to experience delayed or incomplete diagnostic pursuit. Stigma can reduce both care-seeking behavior and clinician responsiveness, contributing to underrecognition.

Physician Education Gap

Provider knowledge is a critical determinant of diagnosis. Variability in training, clinical exposure, and continuing education can lead to inconsistent recognition of the same condition across providers and settings. Conditions that are less emphasized in medical education or that evolve rapidly may be underdiagnosed due to gaps in provider familiarity.

Diagnostic Limitations

The availability and reliability of diagnostic tools directly affect case capture. Conditions without definitive biomarkers, or those requiring complex, multi-step evaluation, are more vulnerable to misclassification or non-diagnosis. Even when tests exist, access, cost, and interpretation can limit their effective use.

Referral and Specialist Dependency

Many conditions require specialist evaluation for confirmation. When diagnosis depends on access to dermatology, neurology, rheumatology, or other specialty care, barriers such as geographic availability, insurance constraints, and wait times can reduce diagnostic completion rates. Primary care recognition alone is often insufficient in these cases.

Underrecognized Subgroup Burden

Diagnostic systems are influenced by implicit assumptions about who is “typical” for a given condition. Patients who fall outside these expectations, whether due to race, gender, age, or phenotype, may be less likely to be evaluated or correctly diagnosed. This contributes to systematic underrepresentation of certain populations in prevalence data.

Late Detection Bias

Some conditions are disproportionately identified only after progression or complication. In these cases, early-stage disease may remain undetected, and prevalence estimates become weighted toward more severe presentations. This creates a temporal distortion, where diagnosis reflects disease advancement rather than initial onset.

These domains are not independent variables but interacting components of a broader system. In practice, multiple domains often converge, amplifying diagnostic friction and increasing the likelihood of missed or delayed cases. By evaluating these domains collectively, the Diagnostic Multiplier™ estimates the degree to which diagnostic systems filter, delay, or suppress the visibility of disease within population-level data.

5. Standardization Across Conditions

To ensure consistency across disease categories, CYNAERA applies a standardized internal scoring framework that calibrates diagnostic friction across conditions while preserving condition-specific nuance. This enables the Diagnostic Multiplier™ to be applied across a broad range of diseases, including cancers, autoimmune disorders, infection-associated chronic conditions, gynecologic diseases, neurologic conditions, and other clinically underrecognized or unevenly diagnosed illnesses.

Diagnostic capture exists along a spectrum rather than as a binary state. At one end are conditions with relatively strong detection infrastructure. At the other are conditions where diagnosis is fragmented, delayed, or inconsistently applied. The Diagnostic Multiplier™ is designed to operate across this spectrum using a consistent methodological approach.

High-detection conditions

Conditions with established screening pathways, standardized diagnostic criteria, and widespread clinical awareness typically exhibit lower diagnostic friction. These include many cancers such as melanoma, breast cancer, ovarian cancer, cervical cancer, and endometrial cancer. Although detection systems for these conditions are comparatively robust, variation in access to care, provider suspicion, and timing of diagnosis can still produce measurable gaps in case capture, particularly across different populations.

Moderate- to high-friction conditions

Conditions that rely on subjective symptom interpretation, lack definitive biomarkers, or depend heavily on specialist evaluation often exhibit higher levels of diagnostic friction. These include infection-associated chronic conditions and complex multisystem disorders such as Long COVID, ME/CFS, POTS, fibromyalgia, mast cell activation syndrome, and small fiber neuropathy, as well as autoimmune and connective tissue disorders such as Sjögren’s syndrome and Ehlers-Danlos syndrome. Gynecologic conditions including endometriosis, adenomyosis, vulvodynia, pelvic floor dysfunction, and interstitial cystitis also frequently fall into this category due to delayed diagnosis and symptom dismissal. Neurologic and systemic conditions such as chronic migraine and lipedema further illustrate how variability in recognition can shape observed prevalence.

By applying a consistent framework across these categories, the Diagnostic Multiplier™ allows prevalence to be interpreted in the context of diagnostic system performance rather than as a purely biological measure. This makes it possible to compare disease burden across conditions with very different levels of clinical visibility while maintaining methodological coherence.

6. Application Across Disease Categories

Diagnostic capture is not uniform across disease categories, and the performance of diagnostic systems varies based on the structure, maturity, and accessibility of clinical pathways associated with each condition. In oncology, diagnostic infrastructure is relatively well-developed. Screening programs, standardized staging criteria, and widespread clinical awareness support earlier recognition and more consistent case capture. However, even within these systems, meaningful variability persists. Differences in access to dermatology, oncology, and diagnostic imaging, as well as variation in provider suspicion across populations, can influence both the timing and likelihood of diagnosis. These factors contribute to measurable gaps in case capture, particularly in populations that are less frequently perceived as high risk or that present with atypical disease patterns (Siegel et al. 2023; Bradford 2009).

In contrast, conditions that rely on subjective symptom interpretation, lack definitive biomarkers, or require specialized evaluation often exhibit substantially higher levels of diagnostic friction. In these cases, diagnosis is contingent on multiple system interactions, including patient self-advocacy, provider recognition, and access to appropriate referral networks. As a result, observed prevalence may represent only a subset of total cases, particularly in conditions where clinical presentation is heterogeneous or poorly understood (Jason et al. 1999; Hsu et al. 2015).

Between these extremes lies a spectrum of moderate-detection conditions, where diagnostic capture is influenced by a combination of partial awareness, variable access, and evolving clinical guidance. These conditions often exhibit inconsistent prevalence estimates across datasets and regions, reflecting underlying variability in diagnostic performance rather than true biological differences.

The Diagnostic Multiplier™ model provides a unified framework for navigating this variability. By applying a consistent structure across disease categories, it enables prevalence estimation that accounts for both biological and system-level dynamics without requiring condition-specific redefinition of methodology. This allows for direct comparison across conditions while preserving the contextual nuance necessary for accurate modeling.

7. Real-World Example: Melanoma (United States)

Melanoma demonstrates how a condition can have strong diagnostic infrastructure while still exhibiting measurable gaps in detection. We used this in our paper, Personalized CRISPR Remission™ in Melanoma. Although melanoma benefits from established diagnostic pathways, detection can be affected by uneven dermatologic access, lower clinical suspicion in certain populations, and delayed recognition of atypical presentations, particularly in darker skin (Bradford 2009; Cormier et al. 2006).

Observed U.S. prevalence is approximately 1.50 million individuals.

Applying the Diagnostic Multiplier™:

Adjusted Prevalence = 1.50M × 1.12 = 1.68M

CYNAERA U.S. Adjusted Melanoma Estimate: ~1.68 million individuals

This adjustment reflects incomplete diagnostic capture while remaining consistent with prior CYNAERA oncology modeling patterns, which apply modest upward corrections to reflect real-world detection variability.

8. Why the Model Works

The Diagnostic Multiplier™ improves prevalence estimation by explicitly incorporating diagnostic system behavior into quantitative modeling. Rather than treating observed data as a neutral reflection of disease burden, it recognizes that diagnosis is an active process shaped by clinical, structural, social, and environmental dynamics. A central premise of the model is that diagnosis is not uniformly distributed. The likelihood that a condition is identified depends on factors such as provider familiarity, access to care, availability of diagnostic tools, the degree to which symptoms are taken seriously, and whether environmental exposures that influence disease severity are recognized in clinical assessment. These factors vary across conditions, populations, and healthcare settings, introducing systematic distortion into observed prevalence.

As a result, recorded case counts reflect not only how often a disease occurs, but how effectively it is recognized. In high-performing diagnostic systems, this gap may be relatively small. In others, particularly where access is uneven, recognition is inconsistent, or environmental triggers are overlooked, the gap can be substantial.

The Diagnostic Multiplier™ addresses this by modeling diagnostic friction as a measurable component of prevalence. By accounting for barriers such as delayed recognition, referral dependence, subgroup underrecognition, and incomplete incorporation of environmental exposures into diagnostic reasoning, the model adjusts observed data to better approximate total burden. This approach is consistent with broader epidemiological and health systems research showing that differences in access, provider education, clinical pathways, and exposure burden can significantly influence detection rates and outcomes.

Importantly, the model does not assume that all conditions are equally underdetected. Instead, it allows for graded adjustment, reflecting differences in diagnostic infrastructure and system performance. Conditions with robust screening and widespread clinical awareness receive smaller adjustments, while those with fragmented recognition, symptom overlap, or poorly integrated environmental context receive larger ones. This preserves biological and clinical nuance while still correcting for systemic distortion.

The model also aligns with real-world patterns across both cancer and chronic disease. Conditions that are diagnosed later in certain populations or settings often show worse outcomes, not only because of disease biology, but because recognition occurred after progression, complication, or prolonged exposure to worsening triggers. This is especially relevant in diseases influenced by air quality, mold exposure, wildfire smoke, heat, housing conditions, water damage, pollution, and other environmental risk factors, where environmental burden may intensify symptoms, alter presentation, or accelerate progression before diagnosis occurs.

By integrating these realities, the Diagnostic Multiplier™ creates a bridge between epidemiological data and lived disease burden. It shifts prevalence estimation from a static count of diagnosed cases to a more dynamic representation of how disease is actually recognized within real-world systems shaped by access, clinical behavior, and environmental exposure. In doing so, the model produces estimates that are not only more accurate, but more actionable. It helps researchers, clinicians, institutions, and policymakers identify where diagnostic gaps exist, quantify their downstream impact, and design better approaches to detection, prevention, and response in a world where disease burden is increasingly shaped by both healthcare system performance and environmental conditions.

9. Relationship to CYNAERA Frameworks

The Diagnostic Multiplier™ operates as a core layer within the broader CYNAERA modeling architecture, functioning as the system-level correction mechanism that translates observed data into more accurate representations of real-world burden.

Within this ecosystem, each framework addresses a distinct dimension of disease modeling:

• US-CCUC™ focuses on population-level undercount, particularly where structural disparities lead to systematic exclusion from datasets. It corrects for who is missing from the denominator.

• S³ Model™ captures signal emergence by analyzing patterns in digital, social, and observational data. It identifies when a condition is increasing or being discussed at rates not yet reflected in formal reporting.

• PULSE™ evaluates underreporting risk by integrating media, testimony, and institutional visibility signals to detect gaps between expected and reported trends.

• Diagnostic Multiplier™ (DM™) addresses a separate but equally critical dimension: how effectively healthcare systems convert existing disease into recorded diagnosis. It corrects for how many cases are not captured due to diagnostic system performance.

Together, these frameworks form a layered model:

• Signal Layer (S³, PULSE™) → detects presence and trend

• Population Layer (US-CCUC™) → adjusts for who is counted

• Diagnostic Layer (DM™) → adjusts for what is recognized

This architecture allows CYNAERA to move beyond single-source prevalence estimation and toward a multi-dimensional understanding of disease burden. Rather than relying on any one dataset or methodology, CYNAERA integrates biological, social, and structural factors into a unified modeling system. Importantly, the Diagnostic Multiplier™ serves as the bridge between observed data and system-aware interpretation. It ensures that prevalence estimates reflect not only the existence of disease, but the capacity of systems to detect and record it. This distinction is critical for applications in clinical research, health equity modeling, and policy development.

10. Conclusion

Disease prevalence is often presented as a static measure, derived from counts of diagnosed cases. In reality, prevalence is dynamic and system-dependent. It reflects not only how often a disease occurs, but how effectively it is recognized within the structures designed to detect it.

The Diagnostic Multiplier™ addresses this gap by incorporating diagnostic system performance into prevalence estimation. By accounting for factors such as stigma, provider education, diagnostic accessibility, and delayed recognition, it provides a more complete representation of disease burden across populations and conditions.

This approach has several important implications. It challenges the assumption that observed data is neutral, highlighting the role of structural and clinical factors in shaping what is measured. It supports more accurate allocation of resources by identifying areas where burden is likely underestimated. It improves research design by aligning study populations more closely with real-world prevalence. And it strengthens policy development by providing a clearer picture of population-level need.

As healthcare systems continue to evolve, the ability to distinguish between observed and actual burden will become increasingly important. Models that fail to account for diagnostic variability risk reinforcing existing gaps in care, research, and funding. The Diagnostic Multiplier™ provides a scalable, condition-agnostic method to address this challenge. By integrating diagnostic friction into prevalence estimation, it enables more accurate, equitable, and actionable insights across the full spectrum of disease.

CYNAERA Framework Papers

This paper draws on a defined subset of CYNAERA Institute white papers that establish the methodological and analytical foundations of CYNAERA’s frameworks. These publications provide deeper context on prevalence reconstruction, remission, combination therapies and biomarker approaches. Our Long COVID Library and ME/CFS Library is also and in depth resource.

• Corrected National Prevalence Estimates for (IACCs)

• Personalized CRISPR Remission™ in Melanoma

• One New Long COVID Case Every Minute in the United States

• The Pathophysiology of Infection-Associated Chronic Conditions

•  CYNAERA’s VitalGuard™ Environmental Flare Risk Engine

Author’s Note:

All insights, frameworks, and recommendations in this written material reflect the author's independent analysis and synthesis. References to researchers, clinicians, and advocacy organizations acknowledge their contributions to the field but do not imply endorsement of the specific frameworks, conclusions, or policy models proposed herein. This information is not medical guidance.

Patent-Pending Systems

​Bioadaptive Systems Therapeutics™ (BST) and all affiliated CYNAERA frameworks, including CRISPR Remission™, VitalGuard™, CRATE™, SymCas™, and TrialSim™, are protected under U.S. Provisional Patent Application No. 63/909,951.

Licensing and Integration

CYNAERA partners with universities, research teams, federal agencies, health systems, technology companies, and philanthropic organizations. Partners can license individual modules, full suites, or enterprise architecture. Integration pathways include research co-development, diagnostic modernization projects, climate-linked health forecasting, and trial stabilization for complex cohorts. You can get basic licensing here at CYNAERA Market.

Support structures are available for partners who want hands-on implementation, long-term maintenance, or limited-scope pilot programs.

About the Author 

Cynthia Adinig is a researcher, health policy advisor, author, and patient advocate. She is the founder of CYNAERA and creator of the patent-pending Bioadaptive Systems Therapeutics (BST)™ platform. She serves as a PCORI Merit Reviewer, and collaborator with Selin Lab for T cell research at the University of Massachusetts.

Cynthia has co-authored research with Harlan Krumholz, MD, Dr. Akiko Iwasaki, and Dr. David Putrino, though Yale’s LISTEN Study, advised Amy Proal, PhD’s research group at Mount Sinai through its patient advisory board, and worked with Dr. Peter Rowe of Johns Hopkins on national education and outreach focused on post-viral and autonomic illness. She has also authored a Milken Institute essay on AI and healthcare, testified before Congress, and worked with congressional offices on multiple legislative initiatives. Cynthia has led national advocacy teams on Capitol Hill and continues to advise on chronic-illness policy and data-modernization efforts.

Through CYNAERA, she develops modular AI platforms, including the CRISPR Remission™,  IACC Progression Continuum™, Primary Chronic Trigger (PCT)™, RAVYNS™, and US-CCUC™, that are made to help governments, universities, and clinical teams model infection-associated conditions and improve precision in research and trial design. US-CCUC™ prevalence correction estimates have been used by patient advocates in congressional discussions related to IACC research funding and policy priorities. Cynthia has been featured in TIME, Bloomberg, USA Today, and other major outlets, for community engagement, policy and reflecting her ongoing commitment to advancing innovation and resilience from her home in Northern Virginia.

Cynthia’s work with complex chronic conditions is deeply informed by her lived experience surviving the first wave of the pandemic, which strengthened her dedication to reforming how chronic conditions are understood, studied, and treated. She is also an advocate for domestic-violence prevention and patient safety, bringing a trauma-informed perspective to her research and policy initiatives.

References

1. Bailey, Z. D., Krieger, N., Agénor, M., Graves, J., Linos, N., & Bassett, M. T. (2021). Structural racism and health inequities in the USA. The Lancet, 389(10077), 1453–1463.

2. Bradford, P. T. (2009). Skin cancer in skin of color. Dermatology Nursing, 21(4), 170–178.

3. Clegg, L. X., Reichman, M. E., Miller, B. A., et al. (2002). Impact of socioeconomic status on cancer incidence and stage at diagnosis. Journal of the National Cancer Institute, 94(17), 1313–1321.

4. Cormier, J. N., Xing, Y., Ding, M., et al. (2006). Ethnic differences among patients with cutaneous melanoma. Archives of Internal Medicine, 166(17), 1907–1914.

5. Corrigan, P. W., Druss, B. G., & Perlick, D. A. (2014). The impact of mental illness stigma on care. Psychological Science in the Public Interest, 15(2), 37–70.

6. Hsu, C., Liss, D. T., Westbrook, E. O., et al. (2015). Diagnostic pathways and barriers. Journal of General Internal Medicine, 30(12), 1883–1889.

7. Institute of Medicine. (2003). Unequal Treatment. National Academies Press.

8. Jason, L. A., Richman, J. A., Rademaker, A. W., et al. (1999). Chronic fatigue syndrome prevalence. Archives of Internal Medicine, 159(18), 2129–2137.

9. National Academies of Sciences, Engineering, and Medicine. (2017). Communities in Action. National Academies Press.

10. Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023). Cancer statistics, 2023. CA: A Cancer Journal for Clinicians, 73(1), 17–48.

11. Ward, E., Jemal, A., Cokkinides, V., et al. (2004). Cancer disparities. CA: A Cancer Journal for Clinicians, 54(2), 78–93.